Press Releases

Collaboration extends impact of Wistar’s biomedical science and workforce development programs and Cheyney University’s educational and entrepreneurial communities 

PHILADELPHIA — (July 6, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Chengyu Liang, M.D., Ph.D., as professor in the Molecular & Cellular Oncogenesis Program of The Wistar Institute Cancer Center. 

The Liang laboratory is focused on understanding the mechanisms that regulate fundamental cellular processes such as autophagy, cell death, DNA damage repair, and membrane trafficking in the context of cancer and infectious disease. 

Allevi 3D printed lung models will be used to study SARS-CoV-2 mechanisms of disease progression

PHILADELPHIA — (May. 28, 2020) — Scientists at The Wistar Institute developed a synthetic DNA approach that instructs in vivo production of a human monoclonal antibody able to neutralize hepatitis B virus (HBV) and prevent infection of liver cells in vitro.

PHILADELPHIA — (May 20, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious disease, announces a study reporting initial immunogenicity of a synthetic DNA vaccine for SARS-CoV-2 developed in collaboration with Inovio Pharmaceutical, Inc., and other scientists. Published in Nature Communications, the report focuses on immune studies in animals, which show induction of functional antibody responses and T-cell responses following immunization.